Septerna Emerges With $100m To Target Undruggable GPCRs

Start-Up Pairs Structural Insights With Computational Tools

Septerna’s platform purifies G-coupled protein receptors (GPCR) to identify new drug targeting sites and then uses technologies such as machine learning to find novel compounds against hard-to-reach GPCRs.

Start up concept vector illustration
The start-up is screening GPCR-targeting compounds at scale • Source: Alamy

A third of all approved medicines – more than 700 drugs – target G-protein coupled receptors, but many GPCRs remain unreachable with traditional pharmaceutical approaches. To drug what was once deemed undruggable, Septerna Inc. came out of stealth mode on 27 January with $100m in series A venture capital and a new technology platform to get around the GPCR-targeting problems of the past while using modern tools to discover novel compounds.

Septerna co-founders Jeffrey Finer and Robert Lefkowitz spoke with Scrip about the serendipitous union of CEO Finer’s ideas about GPCR drug discovery with Duke University professor Lefkowitz’s solution to a GPCR research challenge

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.